The clinical trials listed on this page are not specifically designed for fibrolamellar carcinoma, but include FLC patients based on eligibility criteria (basket trials or broader liver cancer studies).
Trials Currently Recruiting That Include FLC Patients
● I‑PREDICT (Molecularly Guided Therapy Study)
- Formal name: Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses (MCW I-PREDICT)
- Trial type: Includes fibrolamellar carcinoma (precision oncology)
- Phase: Phase I / II
- Recruitment status: Active, Recruiting
- Eligible ages: 18 years and older
- Location: Milwaukee, WI (Medical College of Wisconsin)
- ClinicalTrials.gov ID: NCT05674825
- Detail page: View trial details
This phase I trial assesses the use of a personalized medicine approach to cancer treatment. Rather than giving treatment based primarily on the type of cancer (such as liver cancer), the researchers will use detailed molecular and genetic testing of a patient’s tumors to identify individualized therapies that may be effective for that specific patient’s cancer.
● Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- Formal name: ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib with Intravenous Bevacizumab with the Addition of Atezolizumab in Pediatric Solid Tumor Patients
- Trial type: Includes fibrolamellar carcinoma
- Phase: Phase I / II
- Recruitment status: Active, Recruiting
- Eligible ages: less than 30 years old at time of enrollment
- Location: Memphis, TN (St. Jude Children’s Research Hospital)
- ClinicalTrials.gov ID: NCT05468359
- Detail page: View trial details
This phase I/II trial evaluates whether a four-drug combination of cyclophosphamide, sorafenib, bevacizumab, and atezolizumab is safe and effective for children and young adults with rare solid tumors including FLC. The study also aims to determine whether this treatment can stimulate the immune system to better recognize and attack tumor cells, potentially improving outcomes for patients with difficult-to-treat cancers.
● Checkpoint Inhibition in Pediatric Hepatocellular Carcinoma
- Formal name: Checkpoint Inhibition in Pediatric Hepatocellular Carcinoma
- Trial type: Includes fibrolamellar carcinoma
- Phase: Phase II
- Recruitment status: Active, Recruiting
- Eligible ages: Up to 30 years
- Location: Boston, MA (Dana‑Farber Cancer Institute), plus sites in California, Ohio, and Texas
- ClinicalTrials.gov ID: NCT04134559
- Detail page: View trial details
This phase II study evaluates the effectiveness of the immunotherapy drug pembrolizumab as a treatment for pediatric hepatocellular carcinoma.
Important Notes
- These trials are not FLC‑specific, and eligibility criteria vary.
- Patients should consult their oncology team to determine the suitability of the trial to their situation.
- Trial status and enrollment availability may change at any time; please visit clinicaltrials.gov for a comprehensive list of active trials.
The Fibrolamellar Cancer Foundation does not provide medical advice. We provide website users with information to help them better understand their health conditions and current approaches towards diagnosis, treatment and supportive care. Always seek the advice of your physician or other qualified healthcare provider.